EXHIBIT 12

STATEMENT REGARDING COMPUTATION OF RATIOS OF EARNINGS TO FIXED CHARGES

	For the Year Ended														For the Nine Months Ended
Dollar amounts in thousands	Dec. 31, 1999			Dec. 30, 2000			Dec. 29, 2001			Dec. 28, 2002		Dec. 27, 2003			Sept. 27, 2003			Sept. 25, 2004
Earnings:
Earnings before income taxes	$	3,387		$	4,459		$	116,059		$	2,670	$	(13,437	)	$	(271	)	$	(22,506	)
Fixed charges		9,370			9,841			7,752			2,348		2,538			1,638			2,231
Amortization of capitalized interest		—			—			148			1,274		1,273			947			947
Interest capitalized		(4,658	)		(5,795	)		(5,202	)		—		(83	)		—			—
Adjusted earnings		8,099			8,505			118,757			6,292		(9,709	)		2,314			(19,328	)
Fixed charges:
Interest expense		4,313			3,581			2,128			2,130		1,350			570			2,104
Interest capitalized		4,658			5,795			5,202			—		83			—			—
Assumed interest component of rent expense		399			465			422			218		149			112			127
Capitalized expenses related to indebtedness		—			—			—			—		956			956			—
Total fixed charges	$	9,370		$	9,841		$	7,752		$	2,348	$	2,538		$	1,638		$	2,231
Ratio of earnings to fixed charges		N/A			N/A			15.3			2.7		N/A			1.4			N/A

For the year ended December 27, 2003 and the nine months ended September 25, 2004, Nabi Biopharmaceuticals did not generate sufficient earnings to cover its fixed charges by the following amounts

	For the Year Ended								For the Nine Months Ended
	Dec. 31, 1999		Dec. 30, 2000		Dec. 29, 2001	Dec. 28, 2002	Dec. 27, 2003		Sept. 27, 2003	Sept. 25, 2004
Coverage Deficiency	$	1,271	$	1,336	—	—	$	12,247	—	$	21,559